What type of study is this?

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study shows low adherence and high costs for sickle cell patients using L-glutamine after vaso-occlusive crises, indicating care gaps.

Patients had low adherence, with a mean proportion of days covered of 0.37.
Healthcare costs increased by approximately $38,111 after starting chronic therapy, indicating economic burdens.
Sickle cell disease patients experienced frequent vaso-occlusive crises, remaining similar before and after treatment.
Economic outcomes were driven by the costs associated with recently approved therapies like L-glutamine.

Udeze et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective study shows low adherence and high costs for sickle cell patients using L-glutamine after vaso-occlusive crises, indicating care gaps.